Compare Inovio Pharmaceuticals Inc (INO) vs Manhattan Associates Inc (MANH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Inovio Pharmaceuticals Inc vs Manhattan Associates Inc — how do they compare? Inovio Pharmaceuticals Inc trades at $1.09 (market cap $89.27M), while Manhattan Associates Inc trades at $161 (market cap $9.79B). The key difference: Manhattan Associates Inc is far larger — about 109.7× Inovio Pharmaceuticals Inc's market cap, and Manhattan Associates Inc is trading nearer its 52-week high, Inovio Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| INO | MANH | |
|---|---|---|
Market Cap | $89.27M | $9.79B |
Sector | Health | Technology |
52-Week High | $2.87 | $227.94 |
52-Week Low | $1.05 | $120.88 |
Enterprise Value | $60.28M | $9.62B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INO trades at $1.07, down 4.46% today, reflecting persistent bearish technical signals. The company shows minimal revenue of $65.34K (2025) with a net loss of $84.95M, resulting in a negative net margin of 130,000%. Despite beating recent EPS estimates, cash flow remains negative. Key near-term catalyst is the FDA's PDUFA decision on INO-3107 by October 30, 2026.
Outlook hinges on regulatory success for INO-3107; approval could drive significant upside, but failure poses substantial risk. High cash burn and lack of profitability underscore speculative nature. Analyst consensus is cautiously optimistic with 53% buy ratings, yet financial health remains precarious without near-term revenue growth.
Manhattan Associates (MANH) trades at $165.51, up 1.42% today, with a bullish technical outlook supported by moving averages and strong support at $162. The company demonstrates robust fundamentals with a 19.68% net margin and consistent earnings beats in recent quarters. Analyst sentiment remains positive with 73% buy ratings and a $192.80 consensus target, though an ongoing legal investigation has generated negative news flow.
MANH presents a growth opportunity with high profitability and earnings momentum, but faces near-term risks from legal scrutiny and premium valuations. The stock's technical strength and fundamental performance support upside potential, though investors should weigh the legal overhang against strong operational execution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →About Manhattan Associates Inc
Manhattan Associates, Inc. is a global leader in supply chain and omnichannel commerce software. The company provides a comprehensive suite of cloud-based and on-premise solutions for warehouse management (WMS), transportation management (TMS), and order management (OMS). MANH's technology helps retailers, wholesalers, and manufacturers manage inventory, optimize logistics, and unify the shopping experience across physical and digital channels.
Read more on MANH →
